

Extended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007-2012

Daniel Eibach^{a,*,§} (eibach@bnitm.de), Cristina Belmar Campos^{b,*} (c.belmar-campos@uke.de), Ralf Krumkamp^{a,c} (krumkamp@bnitm.de), Hassan M. Al-Emran^a (al-emran@bnitm.de), Denise Dekker^a (dekker@bnitm.de), Kennedy Gyau Boahen^d (gyaukenedy@yahoo.com), Benno Kreuels^b (b.kreuels@uke.de), Yaw Adu-Sarkodie^e (sax@ghanatel.com.gh), Martin Aepfelbacher^b (maepfelbacher@uke.de), Se Eun Park^f (SeEun.Park@ivi.int), Ursula Panzner^f (upanzner@ivi.int), Florian Marks^f (fmarks@ivi.int), Jürgen May^{a,c} (may@bnitm.de)

^a Bernhard Nocht Institute for Tropical Medicine (BNITM), Bernhard-Nocht-Str. 74, 20359 Hamburg, Germany

^b University Medical Centre Hamburg-Eppendorf (UKE), Martinist. 52, 20246 Hamburg, Germany

^c German Centre for Infection Research (DZIF), Hamburg-Borstel-Lübeck, Germany

^d Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana

^e Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana

^f International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742 Republic of Korea

* contributed equally to this work

§ corresponding author

22 Abstract

23 **Background.** High prevalence of Extended Spectrum Beta-Lactamase (ESBL) producing
24 Enterobacteriaceae threatens treatment options for invasive bloodstream infections in sub-
25 Saharan Africa.

26 **Objectives.** To explore the frequency and genotype distribution of ESBL producing
27 Enterobacteriaceae causing bloodstream infections in a primary health care setting in rural
28 Ghana.

29 **Methods.** Blood cultures from all patients with fever $\geq 38^{\circ}\text{C}$ within 24h after admission
30 (community-acquired) and from all neonates with suspected neonatal sepsis (hospital-
31 acquired) were obtained. ESBL-producing isolates were characterized by combined disc test
32 and by amplifying the *bla*CTX-M, *bla*TEM and *bla*SHV genes. Multilocus sequence typing
33 (MLST) was performed for all ESBL-producing *Klebsiella pneumoniae* and *Escherichia coli*
34 isolates, and all *K. pneumoniae* isolates were differentiated by pulsed-field gel electrophoresis
35 (PFGE).

Results. Among 426 Enterobacteriaceae isolated from blood cultures, non-typhoid
Salmonella (n=215, 50.8%), *S. Typhi* (n=110, 26.0%), *E. coli* (n=50, 11.8%) and *K.*
pneumoniae (n=41, 9.7%) were the most frequent. ESBL-producing isolates were restricted to
the CTX-M-15 genotype and the species *K. pneumoniae* (n=34, 82.9%), *Enterobacter cloacae*
complex (n=2, 66.7%) and *E. coli* (n=5, 10.0%). The rates of ESBL-producers in *K.*
pneumoniae were 55.6% and 90.6% in community-acquired and neonatal bloodstream
infections, respectively. MLST and PFGE analysis identified four outbreak clusters among
neonates.

36 **Conclusions.** Considering the rural primary health care study setting, the high proportion of
37 ESBL-producing *Klebsiella pneumoniae* is worrisome and might be devastating in the
38 absence of second line antibiotics. Therefore, enhanced diagnostic laboratories for

39 surveillance purposes and sustainable hospital hygiene measures must be considered to
40 prevent further spread of multidrug resistant bacteria within rural communities.

41

42 **Keywords:** Ghana; Molecular epidemiology; Extended Spectrum β -lactamase; *Klebsiella*
43 *pneumoniae*; Bloodstream infection

44 **Introduction**

45 Enterobacteriaceae that produce plasmid encoded Extended Spectrum β -lactamases (ESBL),
46 are per definition resistant to all β -lactam antibiotics except carbapenems and cephamycins.
47 ESBL-carrying strains frequently show parallel resistance to other antibiotic classes, such as
48 the fluoroquinolones (Bush and Fisher, 2011). The global spread of the CTX-M genotype, in
49 particular CTX-M-15, triggered a shift from clonal hospital outbreaks to the multi-clonal
50 occurrence within and outside the hospital boundaries, making the distinction between
51 nosocomial and community isolates increasingly difficult (Calbo and Garau, 2015; Pitout and
52 Laupland, 2008). Intestinal colonization often precedes bacterial invasion (Pitout and
53 Laupland, 2008), which, in case of bloodstream infections, has been associated in several
54 clinical studies with increased mortality compared to infections with non-ESBL producers
55 (Schwaber and Carmeli, 2007).

56 Notably, in sub-Saharan Africa, where the availability of effective antimicrobial therapies is
57 limited, ESBL-producing bacteria narrow the range of treatment options and increase the
58 likelihood of inadequate empiric treatment (Woerther et al., 2011). This emerging threat has
59 been pointed out in numerous studies within communities in sub-Saharan Africa, which report
60 considerably high intestinal ESBL carriage rates between 10% and 45% (Abdul Rahman and
61 El-Sherif, 2011; Isendahl et al., 2012; Magoué et al., 2013; Schaumburg et al., 2013; Woerther
62 et al., 2011). Data on bloodstream infections caused by ESBL bacteria in Africa are scarce and
63 restricted to major tertiary care referral hospitals where the rate of ESBL isolates ranged
64 between 0.7% (n=1,191) in a Malawian hospital to 75.8% (n=185) in an intensive care unit in
65 Egypt (Gray et al., 2006; Saied et al., 2011).

66 It was reported from the largest tertiary care hospital in Ghana (Korle-Bu Hospital, Accra)
67 that 50% of the *Klebsiella pneumoniae* and 29% of the *Escherichia coli* bloodstream isolates
68 were ESBL producers. However, the study did not distinguish between hospital or community
69 acquired strains and genotyping was not performed (Obeng-Nkrumah et al., 2013). As data

70 from small communities and hospitals within rural areas are not available, existing resistance
71 data might not be representative.

72 This study aims to explore the frequency and genotype distribution of ESBL-producing
73 Enterobacteriaceae causing bloodstream infections in a primary health care setting in a rural
74 community of Ghana.

75

76 **Methods**

77 *Study site and study population*

The study was conducted at the Agogo Presbyterian Hospital, situated in the Asante Akim North district of the Ashanti Region in Ghana. During two recruitment periods, from September 2007 to July 2009 and January 2010 to December 2012, patients of all age groups, who were hospitalized with a tympanic temperature $\geq 38^{\circ}\text{C}$ or a history of fever in the last 24 hours, were enrolled into the study. Additionally, on the neonatal ward all neonates (aged ≤ 28 days) with suspected neonatal sepsis were included into the study. All bloodstream infections were regarded as community-acquired, apart from those identified among neonates, born in the same hospital, which were defined as nosocomial transmitted infections.

78 *Detection and identification of pathogens*

A blood culture was performed at hospital admission or in case of already hospitalized neonates, when a bloodstream infection was suspected. Eight to 10 millilitres of blood being inoculated into a blood culture bottle (BACTEC Plus Aerobic/F, Becton Dickinson, USA) and further processed using a BACTEC 9050 blood culture system (Becton Dickinson, USA) according to the manufacturer's instructions. If less than 3 millilitres of blood were available (e.g., from children) paediatric blood culture bottles were used (BACTEC Peds Plus/F, Becton Dickinson, USA). In case of bacterial growth, subcultures were performed on Columbia

blood, chocolate and MacConkey agar (all Oxoid, Basingstoke, UK). All gram-negative rod shaped bacteria growing on MacConkey agar were identified biochemically by API 20E tests (bioMérieux, Marcy L'Etoile, France) and sent to Germany at -80°C for species confirmation by MALDI-ToF MS (Bruker Daltonics, Bremen, Germany), antibiotic susceptibility testing and subtyping analysis.

79 Antimicrobial susceptibility testing

80 For all Enterobacteriaceae, antimicrobial susceptibility testing was performed with the VITEK
81 2 system using AST-N111 cards (bioMérieux, Marcy L'Etoile, France) according to the 2015
82 European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines
83 (<http://www.eucast.org>). A positive ESBL phenotype was confirmed by the combined disk test
84 with cefotaxime and ceftazidime alone and in combination with clavulanic acid (Becton,
85 Dickinson and Company, Sparks, MD, USA) as described before by the EUCAST (The
86 EUCAST guideline on detection of resistance mechanisms v 1.0 (2013-12-11)).

87 ESBL Genotyping

88 All isolates with ESBL phenotypes were screened for the presence of *bla*CTX-M, *bla*TEM
89 and *bla*SHV genes by Polymerase Chain Reaction (PCR) and subsequent sequencing, as
90 described before (Belmar Campos et al., 2014). In order to further distinguish *bla*CTX-M
91 positive isolates, group specific primers were used for amplification and sequencing, as
92 previously published (Belmar Campos et al., 2014). The resulting sequences were identified
93 by comparison with known sequences using the NCBI BLAST (<http://blast.ncbi.nlm.nih.gov>)
94 and the Lahey Clinic Database (<http://www.lahey.org/studies/>).

95 Subtyping (MLST, PFGE)

96 Multilocus sequence typing (MLST) was conducted for all ESBL-producing *E. coli* and *K.*
97 *pneumoniae* isolates according to previously published 7-loci protocols (Diancourt et al.,
98 2005; Wirth et al., 2006). For all *K. pneumoniae* pulsed-field gel electrophoresis (PFGE) was

99 performed according to the PulseNet protocol for *E. coli*, using a single restriction enzyme
100 digestion with *Xba*I (<http://www.cdc.gov/pulsenet/pathogens/ecoli.html>). PFGE banding
101 patterns were analyzed with InfoQuest FP version 4.5 (Bio-Rad, USA).

102 *Epidemiological analysis*

Categorical variables were described as frequencies and percentages. Continuous variables were described using medians and their corresponding interquartile ranges (IQRs). Case fatality was compared among different populations using the odds ratio (OR) along with the 95%-confidence interval (CI). If indicated, age adjusted ORs (aORs) were calculated using Mantel-Haenszel statistics and age categories of <1, 1 to 4 and >4 years. All data analyses were performed with Stata 14 (StataCorp LP, College Station, USA).

103 *Ethical considerations*

The Committee on Human Research, Publications and Ethics from the School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana provided ethical approval for this study. All participants were informed about the study's purpose and procedures. Written informed consent was obtained prior to study enrolment from all participants or in case of children from their parents or guardian.

104 **Results**

105 *Identification of bacterial bloodstream infections*

*In total, 7,172 blood cultures were performed within the study. Median age of the study participants was 3 years (IQR: 1–18 years) and 50.3 % (n=3,610) were female. Among all study participants, 564 (7.9%) were neonates. Out of 1,215 positive blood cultures, 568 (46.7%) contained a relevant bacterial pathogen. Environmental bacteria and bacteria belonging to the skin flora (e.g., coagulase negative staphylococci, *Corynebacterium* spp. and *Bacillus* spp.) were*

considered as non-pathogenic contaminants. From those 568 blood culture isolates, 423 (74.5 %) bacteria of the Enterobacteriaceae family were cultured. Study participants with Enterobacteriaceae positive blood cultures had a median age of two years (IQR 1–8 years) and 54.8% (n=232) were female. The most frequently identified Enterobacteriaceae were non-typhoid Salmonella (50.8%, n=215) and S. Typhi (26.0%, n=110), followed by E. coli (11.8%, n=50) and K. pneumoniae (9.7%, n=41) (Table 1).

106 Antimicrobial susceptibility

ESBL production was detected in 9.7% (n=41) of the isolated Enterobacteriaceae whereby 82.9% (n=34), 66.7% (n=2) and 10.0% (n=5) of K. pneumoniae, Enterobacter cloacae complex and E. coli were ESBL positive, respectively (Table 1). None of the Salmonella isolates revealed any ESBL activity. Restricted to community-acquired infections, ESBL genotypes were found among 55.6% (n=5) K. pneumoniae and 8.7% (n=4) of E. coli.

Ciprofloxacin resistance was most frequently detected in K. pneumoniae (39.0%; n=16) and E. coli (26.0%; n=13), with 39% (n=16) of K. pneumoniae and 8% (n=4) of E. coli being non-susceptible to ciprofloxacin and concomitantly produced ESBL. In total, 95.1%, 97.6% and 51.2% of ESBL-producing Enterobacteriaceae exhibited parallel resistance to cotrimoxazole (39 out of 41 isolates), gentamicin (40 of 41 isolates) and ciprofloxacin (21 of 41 isolates), respectively. None of the isolates showed reduced susceptibility to carbapenems.

107 ESBL genotyping and subtyping

108 All ESBL-producing isolates harboured the CTX-M-15 ESBL gene. Among the 34 ESBL-
 109 producing K. pneumoniae, sequence types (ST) 13 (38.2%; n=13), ST25 (11.8%; n=4), ST36
 110 (11.8%; n=4) and ST405 (8.8%; n=3) were predominant, while three (60.0%) ESBL-
 111 producing E. coli belonged to ST131 (Figure 1). PFGE was performed for all K. pneumoniae
 112 isolates and demonstrated clusters, which corresponded to the sequence type, except the two

113 ST502 isolates that showed distinct banding patterns (Figure 1). The ST13 cluster comprised
114 community (n=2) as well as nosocomial (n=11) acquired isolates.

115 *Age distribution and neonatal infections*

While most K. pneumoniae (90.2%; n=37) bloodstream infections were observed among children below 4 years of age, the majority of E. coli (74%; n=37) infections were detected in adults and children above 14 years (Table 2). Thirty-two out of 39 Enterobacteriaceae (82.1%) isolated from neonates produced ESBL, the majority of which were K. pneumoniae (74.4 %).

These neonatal ESBL K. pneumoniae could be allocated to different clusters according to MLST and PFGE analysis, depending on different isolation dates during the study (Figure 1 and 2). Invasive bloodstream infections with K. pneumoniae ST25 clustered in March/April 2009 (4 cases), ST13 clustered in March-June 2011 (10 cases), ST36 clustered in September/October 2011 (4 cases) and ST334 clustered in November/December 2011 (2 cases).

116 *Case fatality*

Data on patient's outcome at discharge from the hospital was available for 329 out of 423 patients (77.8%) infected with Enterobacteriaceae. The case fatality of invasive bloodstream infections caused by ESBL-positive Enterobacteriaceae was, with an aOR of 3.0 (95%-CI: 1.2–7.3), significantly higher compared to infections with non-ESBL-producing Enterobacteriaceae. At the neonatology ward, outcome data was available for 40 out of 42 neonates diagnosed with Enterobacteriaceae, showing no mortality difference between bloodstream infections caused by ESBL and non-ESBL-producing Enterobacteriaceae (OR=0.6; 95%-CI: 0.1–3.7).

117

118 Discussion

119 The study results reveal an unequal distribution of ESBL producers among different species of
120 Enterobacteriaceae causing invasive bloodstream infections. While the most commonly
121 detected pathogens non-typhoid *Salmonella* and *S. Typhi* (77% of all isolated
122 Enterobacteriaceae) showed no ESBL production, 82.9%, 66.7% and 10.0% of *K.*
123 *pneumoniae*, *E. cloacae* complex and *E. coli* isolates presented with an ESBL genotype,
124 respectively. A large meta-analysis on community-acquired bloodstream infections in Africa
125 described *Salmonella enterica* as the predominant pathogen as well (Reddy et al., 2010).
126 However, only a low but emerging number of ESBL-producing non-typhoid *Salmonella* in
127 septicemic patients was reported from other sub-Saharan countries, such as Burkina Faso
128 (4.8%), the Democratic Republic of Congo (1.3%) and Tanzania (2.7%) (Blomberg et al.,
129 2005; Lunguya et al., 2013; Maltha et al., 2014). Remarkably, 63.4% of non-typhoid
130 *Salmonella* colonizing the gut of Malian children have been found to harbour ESBL genes
131 (Boisramé-Gastrin et al., 2011).

132 The high proportion of community acquired ESBL-producing *K. pneumoniae* (55.6%) in
133 Ghana is surprising for a rural primary health care hospital and of serious concern. In a study
134 conducted at the largest hospital in Ghana in 2013, a slightly lower percentage (50.0%) of
135 ESBL-producing *K. pneumoniae* was detected in blood cultures, not distinguishing between
136 nosocomial and community acquired cases (Obeng-Nkrumah et al., 2013). The referral
137 hospital in Kumasi reports 37–46% of community acquired *E. coli* and *K. pneumoniae*
138 isolates being ESBL-producers (Ayisi and Adu-Sarkodie, 2015; Feglo et al., 2013).

139 Lower rates of ESBL-producing *K. pneumoniae* have been previously reported from East
140 African tertiary hospitals in Kenya (13%), Tanzania (17%) and for all ESBL-producing
141 Enterobacteriaceae in Malawi (0.7%).(Blomberg et al., 2005; Gray et al., 2006; Kohli et al.,
142 2010) However, those data were collected between 2001 and 2008 and more recent data have

not been published from those countries. Indeed, a more recent study from a South African university hospital reports 76% of *K. pneumoniae* to be ESBL positive.(Dramowski et al., 2015)

Data from comparable rural primary health care settings are limited. In Gabon 49% of *K. pneumoniae* from different infection sites (bloodstream, ear-eye-nose-throat, surgical sites, soft tissue, UTI, wounds) were ESBL producers, while in rural Burkina Faso no ESBL positive *K. pneumoniae*, but 38% of ESBL-positive *E. coli* isolates causing bloodstream infections were reported (Alabi et al., 2013; Maltha et al., 2014).

Consistent with other epidemiological data, the study described here identified ESBL much more frequently in *Klebsiella* than in *E. coli* (Tansarli et al., 2014).

The present study underlines the preeminent role of CTX-M and in particular CTX-M-15. Throughout West and Central Africa CTX-M-15 has been shown to be the predominant genotype detected among all ESBL-producing Enterobacteriaceae species in stool samples, with 84%, 95% and 91% reported from Gabon, Guinea-Bissau and Niger, respectively (Isendahl et al., 2012; Schaumburg et al., 2013; Woerther et al., 2011). In Ghana, 98% of clinical ESBL isolates have been shown to carry the CTX-M-15 gene (Agyekum et al., 2016).

Nosocomial bloodstream infections with multidrug resistant bacteria have been reported from Africa, particularly in vulnerable populations and high-risk areas, such as intensive care units and paediatric departments (Saied et al., 2011; Tansarli et al., 2014). Indeed, an exceptionally high rate (82%) of bloodstream infections among neonates was caused by ESBL Enterobacteriaceae in this study. MLST/PFGE analysis identified four ESBL *K. pneumoniae* clusters, which suggest a nosocomial transmission within the neonatology ward in Ghana.

Even larger multi-clonal outbreaks between February and December 2011 presumably due to horizontal transfer of CTX-M-15 genes between different *Klebsiella* clones, as described before by Guyot et al., cannot be ruled out (Guyot et al., 2012). Clustering of nosocomial

168 ST13 outbreak isolates with community-acquired ST13 isolates in the PFGE analysis
169 demonstrates the blending of hospital and community-acquired ESBL bacteria.
170 Multidrug resistant *Klebsiella* are known to cause hospital outbreaks among neonates in
171 developing, but also developed countries (Mavroidi et al., 2014; Mshana et al., 2013). From a
172 tertiary care hospital in Tanzania multiple outbreaks with CTX-M-15 *K. pneumoniae* among
173 neonatal sepsis patients were reported (Mshana et al., 2013). The authors supposed patient-to-
174 patient or mother-to-child transmission, contaminated equipment or health care workers as
175 possible sources. A later study at the same hospital revealed that 60% of neonates acquired
176 ESBL-producing *K. pneumoniae* and *E. coli* on day 1 after delivery (Nelson et al., 2014).
177 Although mothers colonized with ESBL bacteria are a potential source of ESBL transmission,
178 infection control measures must include health care personnel and environmental
179 contamination. Inadequate hospital hygiene has been demonstrated in Niger and Gabon,
180 where intestinal ESBL carriage rates increased from around 30% at admission to over 90% at
181 hospital discharge (Schaumburg et al., 2013; Woerther et al., 2011). Apart from hospital
182 hygiene, the lack of diagnostic tools, such as blood cultures and antibiotic susceptibility
183 testing, results in the frequent administration of empirical antibiotic therapy and may lead to
184 suboptimal therapy or overtreatment with antibiotics. A more restrictive and rational antibiotic
185 use and control of low-quality antibiotics might help to alleviate the spread of ESBL-
186 producing pathogens in sub-Saharan Africa. Permanent antimicrobial resistance surveillance
187 systems, as established on a temporary basis in Ghana, would substantially improve local
188 infectious disease management (Newman et al., 2011; Opintan et al., 2015).
189 A meta-analysis reports that infections with ESBL-producing Enterobacteriaceae are
190 associated with nearly twice the mortality compared to non-ESBL producers (Schwaber and
191 Carmeli, 2007), which corresponds to the present data. Nevertheless, case fatality seems to be
192 highly dependent on patient age and the high case fatality rate among neonates in the study
193 hospital applies to bloodstream infections regardless of the pathogen's ESBL activity.

This study is limited by the fact that the definition of nosocomial and community-acquired cases is simplistic. As number and lengths of previous hospital stays are often unknown, Enterobacteriaceae detected in blood cultures at the day of admission might still result from a previous hospitalization, which consequently underestimates nosocomial-acquired cases. Neonatal infections caused by ESBL-producing pathogens are commonly classified to be acquired in the hospital (Mshana et al., 2013).

Conclusion

This study reveals a high proportion of invasive bloodstream infections with community acquired ESBL-producing Enterobacteriaceae in a rural community in Ghana, with numbers exceeding those found in university hospitals in sub-Saharan Africa. Beyond community transmission, ESBL-positive *K. pneumoniae* represent a serious threat in neonatal care. Considering the limited availability of second line drugs (e.g. carbapenems) in rural hospitals within sub-Saharan Africa the spread of ESBL-producing Enterobacteriaceae might be devastating. In many parts of sub-Saharan Africa laboratory surveillance of multidrug resistant strains is still impaired by the absence of routine culture and susceptibility testing. The establishment of diagnostic laboratories in rural areas in combination with the application of sustainable hospital hygiene measures must be advanced to control and prevent the dissemination of multidrug resistant bacteria.

Acknowledgements

This work was supported by the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The funders had no role in study design,

218 data collection and analysis, decision to publish, or preparation of the manuscript. The authors
219 declare no conflicts of interest.

220

221 **References**

- 222 Abdul Rahman, E.M., El-Sherif, R.H., 2011. High rates of intestinal colonization with
223 extended-spectrum lactamase-producing Enterobacteriaceae among healthy individuals.
224 J. Investig. Med. 59, 1284–6. doi:10.231/JIM.0b013e318238748e
- 225 Agyekum, A., Fajardo-Lubián, A., Ansong, D., Partridge, S.R., Agbenyega, T., Iredell, J.R.,
226 2016. blaCTX-M-15 carried by IncF-type plasmids is the dominant ESBL gene in
227 Escherichia coli and Klebsiella pneumoniae at a hospital in Ghana. Diagn. Microbiol.
228 Infect. Dis. 84, 328–33. doi:10.1016/j.diagmicrobio.2015.12.010
- 229 Alabi, A.S., Frielinghaus, L., Kaba, H., Kösters, K., Huson, M.A.M., Kahl, B.C., Peters, G.,
230 Grobusch, M.P., Issifou, S., Kremsner, P.G., Schaumburg, F., 2013. Retrospective
231 analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central
232 Africa. BMC Infect. Dis. 13, 455. doi:10.1186/1471-2334-13-455
- 233 Ayisi, L.A., Adu-Sarkodie, Y., 2015. Extended-Spectrum-Beta-Lactamase (ESBL) production
234 among Escherichia coli and Klebsiella species in Kumasi, Ghana. J. Nat. Sci. Res.
- 235 Belmar Campos, C., Fenner, I., Wiese, N., Lensing, C., Christner, M., Rohde, H.,
236 Aepfelbacher, M., Fenner, T., Hentschke, M., 2014. Prevalence and genotypes of
237 extended spectrum beta-lactamases in Enterobacteriaceae isolated from human stool and
238 chicken meat in Hamburg, Germany. Int. J. Med. Microbiol. 304, 678–84.
239 doi:10.1016/j.ijmm.2014.04.012
- 240 Blomberg, B., Jureen, R., Manji, K.P., Tamim, B.S., Mwakagile, D.S.M., Urassa, W.K.,
241 Fataki, M., Msangi, V., Tellevik, M.G., Maselle, S.Y., Langeland, N., 2005. High rate of
242 fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-
243 spectrum beta-lactamases in Dar es Salaam, Tanzania. J. Clin. Microbiol. 43, 745–9.
244 doi:10.1128/JCM.43.2.745-749.2005
- 245 Boissramé-Gastrin, S., Tandé, D., Münck, M.-R., Gouriou, S., Nordmann, P., Naas, T., 2011.
246 Salmonella carriage in adopted children from Mali: 2001-08. J. Antimicrob. Chemother.
247 66, 2271–6. doi:10.1093/jac/dkr307
- 248 Bush, K., Fisher, J.F., 2011. Epidemiological expansion, structural studies, and clinical
249 challenges of new β -lactamases from gram-negative bacteria. Annu. Rev. Microbiol. 65,
250 455–78. doi:10.1146/annurev-micro-090110-102911
- 251 Calbo, E., Garau, J., 2015. The changing epidemiology of hospital outbreaks due to ESBL-
252 producing Klebsiella pneumoniae: the CTX-M-15 type consolidation. Future Microbiol.
253 10, 1063–75. doi:10.2217/fmb.15.22
- 254 Diancourt, L., Passet, V., Verhoef, J., Grimont, P.A.D., Brisse, S., 2005. Multilocus Sequence
255 Typing of Klebsiella pneumoniae Nosocomial Isolates. J. Clin. Microbiol. 43, 4178–
256 4182. doi:10.1128/JCM.43.8.4178-4182.2005
- 257 Dramowski, A., Cotton, M.F., Rabie, H., Whitelaw, A., 2015. Trends in paediatric
258 bloodstream infections at a South African referral hospital. BMC Pediatr. 15, 33.
259 doi:10.1186/s12887-015-0354-3

260 Feglo, P., Adu-Sarkodie, Y., Ayisi, Lord, Jain, R., Spurbeck, R.R., Springman, A.C.,
261 Engleberg, N.C., Newton, D.W., Xi, C., Walk, S.T., 2013. Emergence of a novel
262 extended-spectrum- β -lactamase (ESBL)-producing, fluoroquinolone-resistant clone of
263 extraintestinal pathogenic *Escherichia coli* in Kumasi, Ghana. *J. Clin. Microbiol.* 51,
264 728–30. doi:10.1128/JCM.03006-12

265 Gray, K.J., Wilson, L.K., Phiri, A., Corkill, J.E., French, N., Hart, C.A., 2006. Identification
266 and characterization of ceftriaxone resistance and extended-spectrum beta-lactamases in
267 Malawian bacteraemic *Enterobacteriaceae*. *J. Antimicrob. Chemother.* 57, 661–5.
268 doi:10.1093/jac/dkl037

269 Guyot, K., Biran, V., Doit, C., Moissenet, D., Guillard, T., Brasme, L., Courroux, C.,
270 Maquelin, K., van Leeuwen, W., Vuthien, H., Aujard, Y., De Champs, C., Bingen, E.,
271 2012. Raman spectroscopic analysis of the clonal and horizontal spread of CTX-M-15-
272 producing *Klebsiella pneumoniae* in a neonatal intensive care unit. *Eur. J. Clin.*
273 *Microbiol. Infect. Dis.* 31, 2827–34. doi:10.1007/s10096-012-1636-4

274 Isendahl, J., Turlej-Rogacka, A., Manjuba, C., Rodrigues, A., Giske, C.G., Nauc  r, P., 2012.
275 Fecal carriage of ESBL-producing *E. coli* and *K. pneumoniae* in children in Guinea-
276 Bissau: a hospital-based cross-sectional study. *PLoS One* 7, e51981.
277 doi:10.1371/journal.pone.0051981

278 Kohli, R., Omuse, G., Revathi, G., 2010. Antibacterial susceptibility patterns of blood stream
279 isolates in patients investigated at the Aga Khan University Hospital, Nairobi. *East Afr.*
280 *Med. J.* 87, 74–80.

281 Lunguya, O., Lejon, V., Phoba, M.-F., Bertrand, S., Vanhoof, R., Glupczynski, Y., Verhaegen,
282 J., Muyembe-Tamfum, J.-J., Jacobs, J., 2013. Antimicrobial resistance in invasive non-
283 typhoid *Salmonella* from the Democratic Republic of the Congo: emergence of
284 decreased fluoroquinolone susceptibility and extended-spectrum beta lactamases. *PLoS*
285 *Negl. Trop. Dis.* 7, e2103. doi:10.1371/journal.pntd.0002103

286 Magou  , C.L., Melin, P., Gangou  -Pi  boji, J., Okomo Assoumou, M.-C., Boreux, R., De Mol,
287 P., 2013. Prevalence and spread of extended-spectrum β -lactamase-producing
288 *Enterobacteriaceae* in Ngaoundere, Cameroon. *Clin. Microbiol. Infect.* 19, E416–20.
289 doi:10.1111/1469-0691.12239

290 Maltha, J., Guiraud, I., Kabor  , B., Lompo, P., Ley, B., Bottieau, E., Van Geet, C., Tinto, H.,
291 Jacobs, J., 2014. Frequency of severe malaria and invasive bacterial infections among
292 children admitted to a rural hospital in Burkina Faso. *PLoS One* 9, e89103.
293 doi:10.1371/journal.pone.0089103

294 Mavroidi, A., Liakopoulos, A., Gounaris, A., Goudesidou, M., Gaitana, K., Miriagou, V.,
295 Petinaki, E., 2014. Successful control of a neonatal outbreak caused mainly by ST20
296 multidrug-resistant SHV-5-producing *Klebsiella pneumoniae*, Greece. *BMC Pediatr.* 14,
297 105. doi:10.1186/1471-2431-14-105

298 Mshana, S.E., Hain, T., Domann, E., Lyamuya, E.F., Chakraborty, T., Imirzalioglu, C., 2013.
299 Predominance of *Klebsiella pneumoniae* ST14 carrying CTX-M-15 causing neonatal
300 sepsis in Tanzania. *BMC Infect. Dis.* 13, 466. doi:10.1186/1471-2334-13-466

301 Nelson, E., Kayega, J., Seni, J., Mushi, M.F., Kidenya, B.R., Hokororo, A., Zuechner, A.,
302 Kihunrwa, A., Mshana, S.E., 2014. Evaluation of existence and transmission of extended
303 spectrum beta lactamase producing bacteria from post-delivery women to neonates at
304 Bugando Medical Center, Mwanza-Tanzania. *BMC Res. Notes* 7, 279.
305 doi:10.1186/1756-0500-7-279

306 Newman, M.J., Frimpong, E., Donkor, E.S., Opintan, J.A., Asamoah-Adu, A., 2011.
307 Resistance to antimicrobial drugs in Ghana. *Infect. Drug Resist.* 4, 215–20.
308 doi:10.2147/IDR.S21769

309 Obeng-Nkrumah, N., Twum-Danso, K., Krogfelt, K.A., Newman, M.J., 2013. High levels of
310 extended-spectrum beta-lactamases in a major teaching hospital in Ghana: the need for
311 regular monitoring and evaluation of antibiotic resistance. *Am. J. Trop. Med. Hyg.* 89,
312 960–4. doi:10.4269/ajtmh.12-0642

313 Opintan, J.A., Newman, M.J., Arhin, R.E., Donkor, E.S., Gyansa-Lutterodt, M., Mills-Pappoe,
314 W., 2015. Laboratory-based nationwide surveillance of antimicrobial resistance in
315 Ghana. *Infect. Drug Resist.* 8, 379–89. doi:10.2147/IDR.S88725

316 Pitout, J.D.D., Laupland, K.B., 2008. Extended-spectrum beta-lactamase-producing
317 Enterobacteriaceae: an emerging public-health concern. *Lancet. Infect. Dis.* 8, 159–66.
318 doi:10.1016/S1473-3099(08)70041-0

319 Reddy, E.A., Shaw, A. V, Crump, J.A., 2010. Community-acquired bloodstream infections in
320 Africa: a systematic review and meta-analysis. *Lancet Infect. Dis.* 10, 417–32.
321 doi:10.1016/S1473-3099(10)70072-4

322 Saied, T., Elkholy, A., Hafez, S.F., Basim, H., Wasfy, M.O., El-Shoubary, W., Samir, A.,
323 Pimentel, G., Talaat, M., 2011. Antimicrobial resistance in pathogens causing nosocomial
324 bloodstream infections in university hospitals in Egypt. *Am. J. Infect. Control* 39, e61–5.
325 doi:10.1016/j.ajic.2011.04.009

326 Schaumburg, F., Alabi, A., Kokou, C., Grobusch, M.P., Köck, R., Kaba, H., Becker, K.,
327 Adegnika, A.A., Kremsner, P.G., Peters, G., Mellmann, A., 2013. High burden of
328 extended-spectrum β -lactamase-producing Enterobacteriaceae in Gabon. *J. Antimicrob.*
329 *Chemother.* 68, 2140–3. doi:10.1093/jac/dkt164

330 Schwaber, M.J., Carmeli, Y., 2007. Mortality and delay in effective therapy associated with
331 extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a
332 systematic review and meta-analysis. *J. Antimicrob. Chemother.* 60, 913–20.
333 doi:10.1093/jac/dkm318

334 Tansarli, G.S., Poulikakos, P., Kapaskelis, A., Falagas, M.E., 2014. Proportion of extended-
335 spectrum β -lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa:
336 evaluation of the evidence--systematic review. *J. Antimicrob. Chemother.*
337 doi:10.1093/jac/dkt500

338 Wirth, T., Falush, D., Lan, R., Colles, F., Mensa, P., Wieler, L.H., Karch, H., Reeves, P.R.,
339 Maiden, M.C.J., Ochman, H., Achtman, M., 2006. Sex and virulence in *Escherichia coli*:
340 an evolutionary perspective. *Mol. Microbiol.* 60, 1136–51. doi:10.1111/j.1365-
341 2958.2006.05172.x

342 Woerther, P.-L., Angebault, C., Jacquier, H., Hugede, H.-C., Janssens, A.-C., Sayadi, S., El
343 Mniai, A., Armand-Lefèvre, L., Ruppé, E., Barbier, F., Raskine, L., Page, A.-L., de
344 Rekeneire, N., Andremon, A., 2011. Massive increase, spread, and exchange of extended
345 spectrum β -lactamase-encoding genes among intestinal Enterobacteriaceae in
346 hospitalized children with severe acute malnutrition in Niger. *Clin. Infect. Dis.* 53, 677–
347 85. doi:10.1093/cid/cir522

348

349

350 **Tables**

351 Table 1. Frequency and antibiotic resistance of Enterobacteriaceae causing invasive
352 bloodstream infections (n=423).

Enterobacteriaceae	total (n)	ESBL production [n (%)]	Ciprofloxacin non- susceptibility [n (%)]	Concomitant ESBL production and ciprofloxacin non-susceptibility [n (%)]
Non-typhoid <i>Salmonella</i>	215	0 (0.0)	14 (6.5)	0 (0.0)
<i>S. Typhi</i>	110	0 (0.0)	0 (0.0)	0 (0.0)
<i>Escherichia coli</i>	50	5 (10.0)	13 (26.0)	4 (8.0)
<i>Klebsiella pneumoniae</i>	41	34 (82.9)	16 (39.0)	16 (39.0)
<i>Enterobacter cloacae</i>	3	2 (66.7)	1 (33.3)	1 (33.3)
<i>Proteus mirabilis</i>	3	0 (0.0)	0 (0.0)	0 (0.0)
<i>Leclercia adecarboxylata</i>	1	0 (0.0)	0 (0.0)	0 (0.0)

354

355 Table 2. Age distribution of patients with invasive bloodstream infection caused by
 356 *Enterobacter cloacae* complex, *Escherichia coli* or *Klebsiella pneumoniae*.

agegroups	<i>E. cloacae</i>		<i>E. coli</i>		<i>K. pneumoniae</i>	
	frequency	ESBL production n (%)	frequency	ESBL production n (%)	frequency	ESBL production n (%)
0-7 days	3	2 (66.7)	2	0 (0.0)	30	27 (90.0)
8-28 days	0	0 (0.0)	2	1 (50.0)	2	2 (100.0)
29-365 days	0	0 (0.0)	2	0 (0.0)	3	2 (66.7)
1-4 years	0	0 (0.0)	6	0 (0.0)	2	2 (100.0)
5-14 years	0	0 (0.0)	1	0 (0.0)	0	0 (0.0)
15-59 years	0	0 (0.0)	21	2 (9.5)	3	0 (0.0)
≥ 60 years	0	0 (0.0)	16	2 (12.5)	1	1 (100.0)

357

358

359 Figures

360

361 **Figure 1. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing**

362 **(MLST) of all ESBL-producing *Klebsiella pneumoniae* isolates (n=34).** PFGE clusters

363 correspond to the MLST sequence type, except for two ST502 isolates that show distinct

364 banding patterns. The ST13 cluster comprises community and nosocomial-acquired isolates.

365

366 **Figure 2. Distribution of *Klebsiella pneumoniae* sequence types (n=88).** The figure shows

367 ESBL (coloured boxes) and non-ESBL (dark grey boxes) *Klebsiella pneumoniae* sequence

368 types causing invasive bloodstream infections among all recruited infants on the neonatal

369 ward (age ≤ 28 days) throughout the study period (black line). Clusters can be observed for

370 ST13, ST25, ST36 and ST334.

371

372

Figures

Figure 1




Figure 2

